Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T.

Pediatrics. 2002 Nov;110(5):e56.

PMID:
12415062
3.

Management of protease inhibitor-associated hyperlipidemia.

Penzak SR, Chuck SK.

Am J Cardiovasc Drugs. 2002;2(2):91-106. Review.

PMID:
14727985
4.

Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.

Cahn PE, Gatell JM, Squires K, Percival LD, Piliero PJ, Sanne IA, Shelton S, Lazzarin A, Odeshoo L, Kelleher TD, Thiry A, Giordano MD, Schnittman SM.

J Int Assoc Physicians AIDS Care (Chic). 2004 Jul-Sep;3(3):92-8. Review.

PMID:
15573713
5.

Impact of nevirapine on lipid metabolism.

Clotet B, van der Valk M, Negredo E, Reiss P.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S79-84. Review.

PMID:
14562862
6.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
7.
8.

Metabolic complications associated with antiretroviral therapy.

Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM.

Antiviral Res. 2001 Sep;51(3):151-77. Review.

PMID:
11448728
9.

[HIV-lipodystrophy syndrome].

Mauss S, Schmutz G.

Med Klin (Munich). 2001 Jul 15;96(7):391-401. Review. German.

PMID:
11494914
10.

Strategies for management and treatment of dyslipidemia in HIV/AIDS.

Sax PE.

AIDS Care. 2006 Feb;18(2):149-57. Review.

PMID:
16338773
11.
12.

Evaluation and management of dyslipidemia in patients with HIV infection.

Green ML.

J Gen Intern Med. 2002 Oct;17(10):797-810. Review.

13.

[Dysmetabolic syndrome related to HIV-1 protease inhibitors. Review of the literature and personal data].

Urso R, Croce GF, Tubili C, De Marco M, La Scala P, Luglio D, Narciso P.

Recenti Prog Med. 2000 Feb;91(2):78-85. Review. Italian.

PMID:
10748653
14.

Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review.

Graham NM.

J Acquir Immune Defic Syndr. 2000 Oct 1;25 Suppl 1:S4-11. Review.

PMID:
11126425
15.

Disorders of glucose metabolism in patients infected with human immunodeficiency virus.

Dubé MP.

Clin Infect Dis. 2000 Dec;31(6):1467-75. Epub 2000 Nov 29. Review.

PMID:
11096014
16.

Does antiretroviral-induced hyperlipidaemia constitute a cardiovascular risk?

Gilleece Y, Nelson M.

J HIV Ther. 2001 May;6(2):37-9. Review. No abstract available.

PMID:
11501202
17.

Management of dyslipidemia in patients with HIV disease.

Manfredi R.

Clin Microbiol Infect. 2000 Nov;6(11):579-84. Review.

18.

LIPID abnormalities in patients infected with human immunodeficiency virus.

Mikhail NE.

Endocr Pract. 2008 May-Jun;14(4):492-500. Review.

PMID:
18558606
19.

Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.

Nolan D, John M, Mallal S.

Antivir Ther. 2001 Sep;6(3):145-60. Review.

PMID:
11808750
20.

A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management.

Neto MG, Zwirtes R, Brites C.

Braz J Infect Dis. 2013 Nov-Dec;17(6):691-700. doi: 10.1016/j.bjid.2013.05.004. Epub 2013 Jul 31. Review.

Supplemental Content

Support Center